ANTI-OBESITY DRUGS - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 33 companies including many key and niche players such as -

Arena Pharmaceuticals, Inc.
GlaxoSmithKline Plc
Novo Nordisk
Orexigen Therapeutics, Inc.
Rhythm Pharmaceuticals


Click here to request a full list of companies covered in the report...

Code: MCP-1722
Price: $4950
Companies: 33
Pages: 135
Date: May 2014
Market Data Tables: 49

Complimentary Market Brief:


Request a Complimentary Copy of the Report Insights, Key Findings, Drivers, Trends, Program Sources, and Methodology.
Salutation:
First Name:
Last Name:
Email ID: (Domain Specific Email Required)
Company:
NOTE: Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSN etc. cannot be used

 TABLE OF CONTENTS


 
   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Anti-Obesity Therapeutics - A Significantly Underserved Market.....II-11$100
   Obesity: An Unmet Medical Need.....II-2
Currently Available Drugs.....II-2
1$100
   List of Currently Available Drugs for the Treatment of Obesity.....II-31$100
   The United States – The Largest Obesity and Anti-Obesity Market.....II-4
Europe – A Market with Vast Potential.....II-4
Emerging Economies to Lead Growth.....II-4
1$100
   Table 1: Global Obesity Prevalence (2013): Percentage Share Breakdown of Obese Population
  by Leading Countries (includes corresponding Graph/Chart).....II-5
1$100
   Drug Withdrawals Alter Competition Metrics.....II-6
Unfavorable Reimbursement Levels Hamper Growth.....II-6
1$100
   New Entrants to Induce Competition.....II-7
Anti-Obesity Drugs Under Pipeline.....II-7
1$100
   Alarming Rise in Global Obesity Levels – The Major Growth Factor.....II-81$100
   Table 2: Classification of BMI.....II-9
Table 3: Overweight and Obese Population (Millions) for 2013 in Select Geographic Regions
  (includes corresponding Graph/Chart).....II-9
Table 4: Global Obesity Levels by Leading Countries and Others (2013): Percentage
  Breakdown of Obese Population for the United States, India, China, Mexico, the United
    Kingdom, Germany, Spain, Australia, Canada, Japan, Greece, South Korea, Portugal,
      Slovakia, New Zealand, Finland, Switzerland, Ireland, and Others (includes corresponding
        Graph/Chart).....II-9
1$350
   Table 5: Abdominal Obesity Prevalence (%) by Region and Gender (includes corresponding
  Graph/Chart).....II-10
Growing Emphasis on Metabolism.....II-10
New Research Aids in Discovery of Novel Drugs.....II-10
Cyclic Guanosine Monophosphate Signaling – The Future of Anti-Obesity
  Pharmacotherapy?.....II-10
1$100
   Childhood Obesity – A Market with Unmet Needs.....II-11
Online Drug Stores Boost Sales.....II-11
1$100
   Barriers to Development of Effective Drugs.....II-12
Regulatory Additions – A Barrier to Entry?.....II-12
High Drug Development Costs – A Major Setback.....II-12
1$100
   Weight Loss Alternatives – A Market Dampener.....II-13
Short Treatment Duration – A Major Limiting Factor for Market Growth.....II-13
Product Labelling Could Deter Treatment Continuation.....II-13
1$100
   Orexigen Completes Phase 3 Clinical Trials for NB32.....II-14
Empatic™ Completes Phase II.....II-14
Zafgen Completes Phase II Trial of Beloranib.....II-14
Novo Nordisk Completes Phase III trial of Liraglutide.....II-14
Rhythm Pharmaceuticals Commences Phase 2 Trials for RM 493.....II-14
1$100
   University of Michigan to Commence Trial of Amlexanox in Treating Obesity.....II-151$100
   Study Links PAR2 Protein Amount to Obesity.....II-16
Scientists at Cambridge University Discover Hunger Gene.....II-16
Ghrelin Hormone Linked to Hunger and Obesity.....II-16
1$100
   Diagnosis of Obesity.....II-17
BMI Calculation and Classification.....II-17
Waist Circumference and BMI.....II-17
1$100
   Types of Obesity.....II-18
Monogenic Obesity.....II-18
Polygenic Obesity.....II-18
Causes of Obesity.....II-18
Unhealthy Eating Habits.....II-18
Environmental and Genetic Factors.....II-18
1$100
   Sedentary Lifestyle.....II-19
Alcohol Intake.....II-19
Childhood Obesity.....II-19
Psychological Factors.....II-19
Pregnancy.....II-19
Hormonal Disorders.....II-19
Drugs.....II-19
1$100
   Aging.....II-20
Risks Associated with Obesity.....II-20
1$100
   Dietary Therapy.....II-21
Exercise Therapy.....II-21
Behavior Therapy.....II-21
Pharmacotherapy.....II-21
Weight Loss Surgery.....II-21
Invasive Vis-ΰ-vis Non-invasive Procedures.....II-21
1$100
   A Brief Review of Select Invasive Procedures.....II-22
Bariatric Surgery.....II-22
Laparoscopic Adjustable Gastric Banding (LAGB).....II-22
Vertical Banded Gastroplasty (VBG).....II-22
Roux-en-Y Gastric Bypass Procedure (RYGB).....II-22
Lap-Band Procedure.....II-22
Gastric Band Procedure.....II-22
Gastric Bypass Procedure.....II-22
Doudenal Switch.....II-22
1$100
   Prescription Drugs Vis-ΰ-vis Non-Prescription Drugs.....II-23
Table 6: Obesity Treatment Options and Corresponding Success Rate.....II-23
1$350
   Introduction.....II-24
Mechanism of Action.....II-24
1$100
   Review of Available Prescription Anti-Obesity Drugs.....II-25
Phentermine.....II-25
Orlistat.....II-25
Belviq (Lorcaserin).....II-25
1$100
   Phentermine/Topiramate Cocktail.....II-26
Table 7: Global Anti-obesity Prescription Drugs Market (2012): Percentage Share Breakdown
  of Prescriptions by Physician Practices - Primary Care Physicians (PCP), Internal
    Medicine, Obstetrics/Gynecology, Endocrinology/Diabetes, Psychiatry/Neurology, Cardiology
      and Others (includes corresponding Graph/Chart).....II-26
1$350
   Novo Nordisk to Launch Anti-Obesity Drug in Mexico.....II-27
Orexigen Optimistic of FDA Approval for Contrave.....II-27
Arena Extends Belviq Distribution Agreement with Eisai.....II-27
Sorrento Partners Scripps Research.....II-27
MedImmune Partners NGM Biopharmaceuticals to Develop Anti-Obesity Therapy.....II-27
Arena Launches Belviq.....II-27
1$100
   Kitozyme Signs Deal with Corona.....II-28
GSK and Vanderbilt Sign Agreement for New Anti-Obesity Drug.....II-28
ScinoPharm Signs Agreement for Contract Manufacturing.....II-28
Vivus Launches Qsymis.....II-28
ScinoPharm Enters Supply Deal with Vivus.....II-28
1$100
   Arena Pharmaceuticals, Inc. (US).....II-29
F. HOFFMANN-LA ROCHE LTD. (Switzerland).....II-29
1$100
   GlaxoSmithKline Plc. (UK).....II-30
Novo Nordisk (Denmark).....II-30
Orexigen Therapeutics, Inc. (US).....II-30
1$100
   Rhythm Pharmaceuticals (US).....II-31
VIVUS, Inc. (US).....II-31
Zafgen Inc. (US).....II-31
1$100
   Table 8: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by
  Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (Excl. Japan), Latin America
    and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million
      for Years 2013 through 2020 (includes corresponding Graph/Chart).....II-32
1$350
   Table 9: World Historic Review for Anti-Obesity Drugs by Geographic Region - US, Canada,
  Japan, Europe, Asia-Pacific (Excl. Japan), Latin America and Rest of World Markets
    Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 through
      2012 (includes corresponding Graph/Chart).....II-33
1$350
   Table 10: World 15-Year Perspective for Anti-Obesity Drugs by Geographic Region -
  Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (Excl.
    Japan), Latin America and Rest of World Markets for Years 2006, 2014 and 2020 (includes
      corresponding Graph/Chart).....II-34
1$350
   A. Market Analysis.....III-1
Table 11: US Weight Loss Market by Major Product Segment (2013): Percentage Share
  Breakdown of Revenues for Diet Drinks, Health Clubs, Bariatric Surgery, Diet Foods,
    Artificial Sweeteners, Weight Loss Centers, Medically Supervised Programs, Meal
      Replacements & Appetite Suppressants, Prescription Drugs, Low Calorie Diet Programs, and
        Others (includes corresponding Graph/Chart).....III-1
1$200
   Competitive Scenario.....III-2
Obesity Catching Them Young.....III-2
Table 12: US Childhood Obesity by Age-Group (2013): Percentage of Obese Population
  (includes corresponding Graph/Chart).....III-2
1$200
   Penetration of Anti-Obesity Drugs Remains Poor.....III-3
Key Statistics.....III-3
Table 13: US Obesity Rates by Ethnicity for Men & Women: 2013 (includes corresponding
  Graph/Chart).....III-3
Table 14: Proportion (%) of Obesity in the US Overweight Population by Age Group
  (includes corresponding Graph/Chart).....III-3
1$200
   Table 15: Obesity Prevalence in US Adults by Type (2013) (includes corresponding
  Graph/Chart).....III-4
Table 16: US Obesity Prevalence by Age-group: 2013 (includes corresponding
  Graph/Chart).....III-4
Table 17: US Obesity Prevalence by Annual Income Level (%): 2013 (includes corresponding
  Graph/Chart).....III-4
1$200
   State-wise Stats.....III-51$75
   Table 18: US Obesity Prevalence by Top Cities (% of Total Population): 2013 (includes
  corresponding Graph/Chart).....III-6
Table 19: US Prevalence of Obesity by Top States (% of Total Population): 2013 (includes
  corresponding Graph/Chart).....III-6
1$200
   Reimbursement Scenario.....III-7
Regulatory Environment.....III-7
1$75
   High Development Costs – A High Entry Barrier for Drug Makers.....III-8
Lack of Overall efficacy and outcomes data – A Dampener.....III-8
Obesity and Related Ailments: Burden on Societal and Economic Costs.....III-8
1$75
   Product Launches.....III-9
Strategic Corporate Developments.....III-9
1$75
   Select Key Players.....III-101$75
   B. Market Analytics.....III-11
Table 20: The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-11
1$200
   Table 21: The US Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales
  Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-12
1$200
   Market Analysis.....III-13
Table 22: Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-13
1$200
   Table 23: Canadian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual
  Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-14
1$200
   Market Analysis.....III-15
Table 24: Japanese Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-15
1$200
   Table 25: Japanese Historic Review for Anti-Obesity Drugs Market Analyzed with Annual
  Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-16
1$200
   A. Market Analysis.....III-17
Europe - an Opportune Market for Chronic Weight Management Drugs.....III-17
Prevalence of Obesity in Europe.....III-17
1$75
   Table 26: Obese and Overweight & Obese Population in the European Union (2013):
  Percentage Share Breakdown by Age Group (includes corresponding Graph/Chart).....III-18
Table 27: Select EU Member Countries Ranked by Obesity Rates (2013): Percentage Share of
  Domestic Obese Population in Global Obese Population (includes corresponding
    Graph/Chart).....III-18
1$200
   Table 28: Obesity Prevalence in Select EU Countries (2013) by Gender (%) (includes
  corresponding Graph/Chart).....III-19
1$75
   B. Market Analytics.....III-20
Table 29: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by
  Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets
    Independently Analyzed with Annual Sales Figures in US$ Million for Years 2013 through
      2020 (includes corresponding Graph/Chart).....III-20
1$200
   Table 30: European Historic Review for Anti-Obesity Drugs by Geographic Region/Country -
  France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual
    Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
      Graph/Chart).....III-21
1$200
   Table 31: European 15-Year Perspective for Anti-Obesity Drugs by Geographic Region/
  Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of
    Europe Markets for Years 2006, 2014 and 2020 (includes corresponding
      Graph/Chart).....III-22
1$200
   A. Market Analysis.....III-23
Changing Lifestyle Alters Health Profile.....III-23
1$75
   B. Market Analytics.....III-24
Table 32: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-24
1$200
   Table 33: French Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales
  Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-25
1$200
   A. Market Analysis.....III-26
The Largest Anti-Obesity Market in Europe.....III-26
B. Market Analytics.....III-26
Table 34: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-26
1$200
   Table 35: German Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales
  Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-27
1$200
   Market Analysis.....III-28
Table 36: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-28
1$200
   Table 37: Italian Historic Review for Anti-Obesity Drugs Market Analyzed with Annual
  Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-29
1$200
   A. Market Analysis.....III-30
Anti-Obesity Drugs - the Need of the Hour as NHS Firefights Rising Peril of
  Obesity.....III-30
GlaxoSmithKline Plc – A Key Player.....III-30
1$200
   Strategic Corporate Development.....III-311$75
   B. Market Analytics.....III-32
Table 38: The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market
  Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020 (includes
    corresponding Graph/Chart).....III-32
1$200
   Table 39: The UK Historic Review for Anti-Obesity Drugs Market Analyzed with Annual Sales
  Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-33
1$200
   A. Market Analysis.....III-34
Review of Select Markets.....III-34
Spain.....III-34
Belgium.....III-34
The Netherlands.....III-34
Finland.....III-34
1$75
   Sweden.....III-35
Strategic Corporate Development.....III-35
Key Players.....III-35
2$150
   B. Market Analytics.....III-37
Table 40: Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs
  Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020
    (includes corresponding Graph/Chart).....III-37
1$200
   Table 41: Rest of European Historic Review for Anti-Obesity Drugs Market Analyzed with
  Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-38
1$200
   A. Market Analysis.....III-39
Brief Review of Select Countries.....III-39
Australia.....III-39
Table 42: Australian Obesity & Overweight Prevalence (2013): Percentage Share Breakdown
  of Population for Obese/Overweight, Healthy Weight and Underweight Categories (includes
    corresponding Graph/Chart).....III-39
1$200
   Historic Perspective:.....III-40
Table 43: Prevalence Rate (%) of Overweight/Obese Students in Australia (includes
  corresponding Graph/Chart).....III-40
China.....III-40
1$200
   India.....III-41
Korea.....III-41
Use of Diet Pills Lack Proper Monitoring.....III-41
New Zealand.....III-41
Strategic Corporate Developments.....III-41
1$75
   B. Market Analytics.....III-42
Table 44: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs
  Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020
    (includes corresponding Graph/Chart).....III-42
1$200
   Table 45: Asia-Pacific Historic Review for Anti-Obesity Drugs Market Analyzed with Annual
  Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-43
1$200
   A. Market Analysis.....III-44
Mexico – A Review.....III-44
1$75
   B. Market Analytics.....III-45
Table 46: Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs
  Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020
    (includes corresponding Graph/Chart).....III-45
1$200
   Table 47: Latin American Historic Review for Anti-Obesity Drugs Market Analyzed with
  Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-46
1$200
   Market Analysis.....III-47
Table 48: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs
  Market Analyzed with Annual Sales Figures in US$ Million for Years 2013 through 2020
    (includes corresponding Graph/Chart).....III-47
1$200
   Table 49: Rest of World Historic Review for Anti-Obesity Drugs Market Analyzed with
  Annual Sales Figures in US$ Million for Years 2006 through 2012 (includes corresponding
    Graph/Chart).....III-48
1$200
  
Total Companies Profiled: 33 (including Divisions/Subsidiaries - 34)

Region/Country Players

The United States 14 Japan 4 Europe 8 The United Kingdom 3 Rest of Europe 5 Asia-Pacific (Excluding Japan) 8
Click here to request a full table of contents and more details on this project.